echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Zejing Pharmaceutical's Class 1 new drug ``Donafinil Tosylate Tablets'' will soon be approved for advanced liver disease...

    Zejing Pharmaceutical's Class 1 new drug ``Donafinil Tosylate Tablets'' will soon be approved for advanced liver disease...

    • Last Update: 2021-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 31, the NMPA official website showed that Zejing Pharmaceutical’s Class 1 new drug "Donafinil Tosylate Tablets" has completed the listing review and entered the approval status.


    Donafinil tosylate tablets are oral multi-target, multi-kinase inhibitors, small molecule anti-tumor drugs with independent intellectual property rights developed by Zejing Pharmaceuticals, and belong to Class 1 new drugs.


    Preclinical pharmacological studies have confirmed that Donafenib can not only inhibit the activity of VEGFR, PDGFR and other receptor tyrosine kinases, but also directly inhibit various Raf kinases, and inhibit the downstream Raf/MEK/ERK signal transduction pathway , Inhibit the proliferation of tumor cells and the formation of tumor blood vessels, and exert the anti-tumor effect of multiple inhibition and multi-target blocking.


    This new drug marketing application is mainly based on the results of an open, randomized, parallel controlled, multi-center phase II/III clinical study of Donafenib tosylate tablets for the first-line treatment of advanced hepatocellular carcinoma (trial code ZGDH3).


    The above-mentioned clinical trial results were selected as an oral report at the 2020 ASCO annual meeting.


    From March 2016 to April 2018, a total of 668 patients were enrolled (ITT set, 334 cases in each group), of which 659 cases (328 vs 331 cases) were included in the FAS set.


    In the two groups, 191 cases (57.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.